News and Trends 1 Sep 2017Allergan Takes to the Clinic a New Alzheimer’s Drug from a €3Bn Deal Allergan's partner Heptares Therapeutics has dosed the first patient with a GPCR drug to treat major symptoms of Alzheimer's disease.… September 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2017Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials Bayer's and Regeneron's blockbuster Eylea could be facing serious competition, as Novartis boasts with positive Phase III results for AMD.… June 20, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 18 Apr 2017Two Big Pharma Players Team up to Take Over the NASH Space Allergan has entered a clinical collaboration with Novartis to run a Phase IIb study combining its immunomodulator and Novartis' FXR agonist… April 18, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 15 Mar 2017Allergan makes a deal with Editas to License CRISPR Programs for Eye Disease Allergan has signed a deal with Editas Medicine to access its CRISPR technology and license up to five of its… March 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 Dec 2016The Largest Deals, Fundraising and Exits of 2016 in European Biotech Curious about which technologies have attracted the most cash in biotech finance this year? Here's a list of the most impressive cash… December 26, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Apr 2016Allergan Signs Massive €3Bn Alzheimer’s Deal with UK Biotech Heptares Therapeutics is licensing its portfolio of novel candidates for neurological diseases, including one for Alzheimer's, to Allergan for up to… April 7, 2016 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 25 Nov 2015Novartis Attacks Amgen. Amgen wants to Ruin Roche – The New Biosimilar War! Novartis is hitting back in the Biosimilar battleground: now Neulasta, the white blood cell booster for Cancer, is the latest… November 25, 2015 - 4 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2015Finally, Pfizer acquires Botox-maker Allergan for €150Bn to move to tax-friendly Ireland! The Rumor became more and more tangleon what is now the biggest Pharma deal ever. The Rumor was pumped up… November 23, 2015 - 1 minutemin - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 29 Oct 2015To beat J&J, Pfizer attempts a New Merger…Guess who’s the Target this Time?! Mergers & acquisitions (or M&A in short) have ruled the world of Pharma for a while and the company which seems… October 29, 2015 - 2 minutesmins - By Jerome Topsent Share WhatsApp Twitter Linkedin Email
News and Trends 25 Sep 2015Roche’s patent halts an Amgen biosimilar debut Amgen has had great success with its Avastin biosimilar, used as an inhibitor of angiogenesis in tumor growth. However, despite… September 25, 2015 - 2 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 26 Aug 2015Oh dear, Allergan is doing its 4th product recall in 2015 … Allergan is fighting with manufacturing problems - again! The packaging of some eye treating products were defective and contaminated the… August 26, 2015 - 2 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2015Allergan Continues its Serial Acquisitions to be a Giant Drugmaker With Allergan's absorption by Actavis last year, we ask ourselves, will the newly formed company enter the World's Top Ten drugmaker companies… July 28, 2015 - 3 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 24 Nov 2014Will New Actavis-Allergan Entity Lead to Be in the World Top 10 Drugmakers Companies? The US pharmaceutical company Allergan, known for their Botox, agreed an Actavis bid of 53 billion euros, they permanently passed… November 24, 2014 - 2 minutesmins - By Julie Lellouche Share WhatsApp Twitter Linkedin Email